<ns4:p>The term spondyloarthritis refers to a group of immune-mediated diseases characterised by inflammation the axial skeleton, peripheral joints, and entheses. Ankylosing spondylitis (AS) is most common characteristic these entities even though it was first described over two centuries ago, understanding underlying disease mechanism remains incomplete. It known that around 40% patients with AS have subclinical bowel inflammation, suggesting origin could be in gut. Also, more genes new...

Subclinical synovitis occurs in a third of individuals at risk rheumatoid arthritis. The objective this study was to assess the reversibility subclinical arthritis who are positive for anti-cyclic citrullinated peptide (CCP) antibody with musculoskeletal symptoms and investigate factors associated its resolution within 12 months.

Background: Inflammatory arthritis (IA) is an immune-related condition defined by the presence of clinical synovitis. Its most common form rheumatoid arthritis. Objective: To develop scores for predicting IA in at-risk persons using multidimensional biomarkers. Design: Prospective observational cohort study. Setting: Single-center, Leeds, United Kingdom. Participants: Persons with new musculoskeletal symptoms, a positive test result anticitrullinated protein antibodies, and no synovitis...

Objectives To investigate, in anti-cyclic citrullinated peptide antibody positive (CCP+) at-risk individuals without clinical synovitis, the prevalence and distribution of ultrasound (US) bone erosions (BE), their correlation with subclinical synovitis association development inflammatory arthritis (IA). Methods Baseline US scans 419 CCP+ were analysed. BE evaluated classical sites for rheumatoid damage: second fifth metacarpophalangeal (MCP2 MCP5) joints, metatarsophalangeal (MTP5) joints....

To 1) determine the prevalence of anti-cyclic citrullinated peptide 3 (anti-CCP3) antibodies in anti-CCP2 antibody-positive (anti-CCP2+) at-risk individuals, and 2) explore additional value anti-CCP3 anti-CCP2+ individuals for predicting progression to inflammatory arthritis.Stored serum samples obtained from 347 (BioPlex 2200; Bio-Rad) without clinical synovitis were tested antibodies. Anti-CCP2 titers categorized as low or high, negative, low, strong. Progression arthritis was defined...

To characterise the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA).Patients with PsA meeting classification criteria for (CASPAR) were recruited. Clinical outcomes recorded, and ultrasonography was conducted to assess grey scale (GS) power Doppler (PD) synovitis, periarticular cortical bone erosions enthesitis. The cohort dichotomised by presence or absence dactylitis.Of 177 patients PsA, those (dactylitic (81/177, 46%)) had higher...

To investigate whether anti-CCP2-positive at-risk individuals with musculoskeletal (MSK) symptoms but without clinical synovitis (CCP2+ at-risk) develop US subclinical before inflammatory arthritis and if can be predicted.First, scans of CCP2+ who developed ('progressors') were reviewed for prior to development. Patients in whom the pre-progression scan was negative conducted >6 months progression excluded. Subsequently, regression analyses performed identify predictors baseline...

Abstract Background Musculoskeletal (MSK) symptoms are among the commonest reasons for primary care assessments; however, few individuals will be diagnosed with an inflammatory arthritis (IA) within following year. The purpose of this study was to investigate, in new MSK symptoms, association between patient factors and risk progression IA, order optimise referrals rheumatology. Methods Individuals ≥16 years old non-specific no clinical synovitis were recruited by across UK from July 2007...

To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with RA.Between October 2017 and 2019, all on RTX-O our centre requiring re-treatment were switched RTX-B unless declined by patient or specified treating clinician. Switch strategy effectiveness was assessed retrospectively using DAS28-CRP(3) RTX retention, remaining as a comparator group.The number switching 255/337 (75.7%) while 82 (24.3%) remained RTX-O. There no difference 4...

Abstract Objectives We aimed to develop a prediction model identifying people presenting primary care with musculoskeletal symptoms likely be anti-CCP positive and therefore at risk of developing rheumatoid arthritis (RA). Methods Participants aged ≥16 years, new-onset non-specific no history clinical synovitis, completed symptom questionnaire had an test. Model development used LASSO-penalised logistic regression, performance was assessed using area under the receiver operating...

To investigate the prevalence, distribution and predictive value for development of inflammatory arthritis (IA) conventional radiography (CR) bone erosions (BE) in anti-CCP positive (CCP+) at-risk individuals with musculoskeletal (MSK) symptoms but without clinical synovitis.Baseline CR hands feet 418 CCP+ were analysed. The presence US-BE was explored anatomical areas which CR-BE reported. Hands at time progression analysed a subset who developed IA (73/123, 59.3%). Logistic regression...

To evaluate the relationship between clinical examination/US synovitis in DMARD-naïve early PsA.Eligible patients underwent matched clinical/US 44-joint assessment for tender and/or swollen joints (TJ/SJ) and US [grey scale (GS) ≥ 2 or power Doppler (PD) 1]. Statistical agreement TJ/SJ, GS PD 1 was calculated by prevalence-adjusted bias-adjusted κ (PABAK). derive probabilities of 2/PD 1, mixed-effects logistic regression-modelled odds TJ/SJ were conducted.In 155 patients, 5616 examination....

<h3>Background</h3> US abnormalities occur in patients with new rheumatoid arthritis (RA) and can also predict the development of clinical synovitis anti-CCP positive musculoskeletal symptoms (MSK) (CCP+) [1]. However, timing relation to has not been longitudinally studied. <h3>Objectives</h3> To investigate whether (grey scale (GS) power doppler (PD)) changes period prior inflammatory (IA) CCP+ individuals compared those who do develop IA. <h3>Methods</h3> were prospectively followed until...

To investigate, in anti-cyclic citrullinated peptide antibody positive individuals with musculoskeletal symptoms but no clinical synovitis (CCP+ at-risk), the additional value of ultrasound (US) for prediction inflammatory arthritis (IA). Furthermore, to define a concise US protocol feasible risk prediction.Demographic and data were collected 417 CCP+ at-risk (Leeds CCP cohort) baseline scan assessing bone erosions 36 joints, follow-up duration ≥24 months. Multivariable binary regression...

Background: In a cohort of Anti-Cyclic Citrullinated Peptide Positive (ACPA+) At-Risk developing inflammatory arthritis (IA) individuals without clinical synovitis, we previously demonstrated the predictive value Power Doppler for progression depending on number joints involved (1). Here update these results in larger population combining all ultrasound (US) features and incorporating them multivariable analysis with clinical, genetic, immunological serological markers. Objectives: To...

<h3>Background</h3> Ultrasound (US) Power Doppler (PD) signal is predictive for the development of inflammatory arthritis (IA) in anti-cyclic citrullinated protein antibodies positive (CCP+) individuals with musculoskeletal (MSK) symptoms but no clinical synovitis (CS) [1]. Our previous data showed a late increase overall US inflammation before development, suggesting that sub-clinical phase could be detected [2]. This abstract describes prediction PD abnormalities months following scan....

Abstract Background/Aims A phase of immunologically imminent rheumatoid arthritis (RA) precedes the onset clinical RA, characterised by increased circulating anti-cyclic citrullinated peptide (anti-CCP) antibodies. Early identification in pre-clinical RA primary care (PC), through targeted anti-CCP testing, could prompt secondary referral for earlier diagnosis, achieving better long-term outcomes. This study aimed to develop a model identifying those likely be positive amongst people...

Abstract Background/Aims Palindromic rheumatism (PR) is a recognised precursor of rheumatoid arthritis (RA). Up to 50% PR patients will progress persistent inflammatory (PIA) but risk factors for progression remain unclear. Analysis this large UK prospective cohort has been used develop the first stratification tool predict PIA. Methods The Leeds was recruited from regional primary and secondary care referrals. defined as ‘a confirmed history/physical examination consistent with episodes...

Objectives To investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP antibody test (anti-CCP2−). Methods 469 anti-CCP2− underwent baseline anti-CCP3 testing (QUANTA Lite CCP3; Inova Diagnostics) received post enrolment 12-month questionnaire. A rheumatologist confirmed or excluded diagnosis IA....

<h3>Background:</h3> A recently published risk stratification model proposed a simple score using 4 biomarkers to identify those at high of developing inflammatory arthritis (IA) for referral secondary care [1]. Meanwhile the pre-clinical phase IA is continuum where evolve. Identifying indicating imminent (6 months) progression would be value. <h3>Objectives:</h3> In IA, 1. describe sequential changes in prior development according stratification, and 2. predictive value IA....

<h3>Background</h3> The efficacy of Golimumab treatment in psoriatic arthritis (PsA) patients has been widely documented. <h3>Objectives</h3> aim this study was to analyse the long-term retention rate golimumab and identify independent predictors drug with PsA including concomitant synthetic disease-modifying antirheumatic drugs (sDMARD) <h3>Methods</h3> Prospective monocentric cohort treated according clinical practice. Study approved by local Ethics Committee. Demographic variables were...

<h3>Background:</h3> Inflammatory bowel disease (IBD) related arthropathy may manifest as peripheral arthritis, dactylitis or enthesitis well inflammatory back pain (IBP) due to sacroiliac joint (SIJ) and/or spinal inflammation. HLA-B27 correlates with the presence of MRI determined SIJ bone marrow oedema (BMO) in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients. The prevalence positivity is low IBD patients already be on therapy that potentially modifies lesions at...